In theory, pharmacological inhibition of oncogenic signaling is an effective strategy to halt cellular proliferation, induce apoptosis and eliminate cancer cells. In practice, drugs (for example, PLX-4032) that inhibit oncogenes like B-RAFV600E provide relatively short-term success in patients, owing to a combination of incomplete cellular responses and the development of resistance. To define the relationship between PLX-4032-induced responses and resistance, we interrogated the contributions of anti-apoptotic BCL-2 proteins in determining the fate of B-RAFV600E-inhibited melanoma cells. Although PLX-4032 eliminated B-RAFV600E signaling leading to marked cell cycle arrest, only a fraction of cells eventually underwent apoptosis. These data proposed two hypotheses regarding B-RAFV600E inhibition: (1) only a few cells generate a pro-apoptotic signal, or (2) all the cells generate a pro-apoptotic signal but the majority silences this pathway to ensure survival. Indeed, the latter hypothesis is supported by our observations as the addition of ABT-737, an inhibitor to anti-apoptotic BCL-2 proteins, revealed massive apoptosis following PLX-4032 exposure. B-RAFV600E inhibition alone sensitized cells to the mitochondrial pathway of apoptosis characterized by the rapid accumulation of BIM on the outer mitochondrial membrane, which could be functionally revealed by ABT-737 to promote apoptosis and loss of clonogenic survival. Furthermore, PLX-4032-resistant cells demonstrated collateral resistance to conventional chemotherapy, yet could be re-sensitized to PLX-4032 by BCL-2 family inhibition in vivo and conventional chemotherapies in vitro. Our data suggest that inhibiting anti-apoptotic BCL-2 proteins will enhance primary responses to PLX-4032, along with reducing the development of resistance to both targeted and conventional therapies.
INTRODUCTION
In numerous tumor types, such as malignant melanoma, colorectal cancer and adenocarcinoma of the lung, oncogenic signaling is required to maintain high levels of cellular proliferation and evade cell death. 1, 2 A classic example of a cancer-associated oncogene is the mutated form of B-RAF, where a substitution of valine to glutamate at amino-acid residue 600 (B-RAF V600E ) renders the kinase hyperactive leading to constitutive mitogen-activated protein kinase (MAPK) signaling, unregulated cell cycle and coordinated silencing of the cell death machinery. [2] [3] [4] [5] In the recent years, small molecules (for example, PLX-4032) have been developed and approved for the treatment of B-RAF V600E -positive cancers, and although oncogenic signaling is effectively blocked in these tumors, the death of tumor cells does not reflect similar rates of success. [6] [7] [8] Moreover, B-RAF V600E -positive patients are exposed to high concentrations of PLX-4032 for several weeks, leading to the rapid development of PLX-4032-resistant tumors and the subsequent requirement for alternative chemotherapeutic strategies. 9, 10 It is hypothesized that targeted (for example, PLX-4032) and conventional (for example, dacarbazine) chemotherapeutic strategies eliminate tumor cells by inducing a form of cell death called apoptosis, which is governed by the BCL-2 family of proteins and mitochondria. 11 Apoptosis proceeds when the BCL-2 family compromises the outer mitochondrial membrane (OMM) allowing for pro-apoptotic factors (for example, cytochrome c) within mitochondria to gain access to the cytoplasm, which leads to caspase activation and the apoptotic phenotype. 12 The BCL-2 family is composed of two types of proteins: anti-apoptotic and pro-apoptotic. 13 Anti-apoptotic proteins (for example, BCL-2, BCL-xL, MCL-1) preserve survival by binding and inhibiting the pro-apoptotic proteins. The pro-apoptotic members are divided into 'effectors' and the 'BH3-only proteins'. The effector proteins BAK and BAX homo-oligomerize into proteolipid pores at mitochondria to release cytochrome c; however, this requires an activation step mediated by the 'direct activator' BH3-only proteins. [14] [15] [16] BID and BIM are the major direct activators and function via their BH3 domains to induce BAK/BAX activation and apoptosis. In most cases, the other BH3-only proteins (for example, BAD and PUMA; referred to as 'sensitizer/de-repressor' BH3-only proteins) only bind to anti-apoptotic BCL-2 proteins and establish the apoptotic threshold by promoting BID and/or BIM activities. 17 Dynamic interactions between the pro-and anti-apoptotic proteins govern cellular fate: agents that promote BID/BIM activity enhance apoptosis, whereas mechanisms that block BID/BIM activity lead to cellular survival and chemotherapeutic resistance. 11 The clinical relevance of the BCL-2 family is highlighted by the development of small-molecule BH3 mimetics (for example, ABT-199, ABT-263, ABT-737) that have entered multiple clinical trials. [18] [19] [20] [21] These mimetics function by lowering the cellular threshold for apoptosis, presumably by decreasing the availability of anti-apoptotic BCL-2 family members that promotes pro-apoptotic protein function at the OMM. At present, there is minimal information on the application of these small molecules in melanoma treatment. 19 In the current study, we were interested in defining the mechanistic intersections between PLX-4032-induced cell death signaling and resistance and interrogated the contributions of the BCL-2 proteins in determining the fate of B-RAF V600E -inhibited cells. We utilized melanoma as a model system to explore the biology of B-RAF V600E , as this is the common oncogene associated with the majority of malignant melanoma cases. 4, 5 Furthermore, B-RAF V600E -positive melanoma patient responses to PLX-4032 have been encouraging but require additional insights to improve primary treatment efficacy and reduce the likelihood of chemoresistance. 6, 22, 23 
RESULTS
Our experiments began by validating that the B-RAF V600E cellular model systems responded to PLX-4032 by decreasing the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2; p44/42). To address this, A375 (B-RAF V600E human malignant melanoma) and MeWo (B-RAF WT human malignant melanoma) were treated with PLX-4032 for 0-24 h, and total cell lysates were analyzed by western blotting. Indeed, PLX-4032 decreased the majority of phosphorylated ERK in the A375 cells, but MeWo remained unchanged ( Figure 1a ). The cellular response to the decrease in ERK signaling reflected a marked inhibition of cellular proliferation as approximately 96% of A375 cells treated with PLX-4032 arrested in the G1 phase of cell cycle after 48 h ( Figure 1b ); while MeWo demonstrated no change in proliferation comparing dimethyl sulfoxide (DMSO; 24.3% in S phase) to PLX-4032 (25.4% in S phase) treatments ( Figure 1c ). Interestingly, when PLX-4032 exposure was extended to 72 h, the treatment promoted a small percentage of cells to undergo cell death, as measured by AnnexinV staining (Figure 1d ). The cell death phenotype was prevented by pre-treatment with zVAD-fmk, a pan-caspase inhibitor, which suggested the mechanism of cell death was apoptosis ( Figure 1e ). Importantly, MeWo demonstrated no apoptotic response to PLX-4032 treatment (Figure 1f ). To ensure that the effects of PLX-4032 were not specific to the A375 cell line, we also evaluated SK-MEL-28, another B-RAF V600E human malignant melanoma line, and although ERK phosphorylation and cell cycle were markedly inhibited, the cell death responses to PLX-4032 were minimal (Supplementary Figures S1A and C).
The results in Figure 1d proposed two hypotheses regarding B-RAF V600E inhibition and cell death signaling: (1) only a few cells generate a pro-apoptotic signal and die following PLX-4032 treatment, or (2) all the cells generate a pro-apoptotic signal, but the majority fail to respond ensuring survival. Pro-apoptotic signaling biochemically arises as the increased expression and/or activation of specific BH3-only proteins, and the major cellular mechanism to inhibit the BH3-only signal is by direct sequestration on the anti-apoptotic BCL-2 repertoire (for example, BID directly inhibited by BCL-2). 13 To determine the contribution of the anti-apoptotic BCL-2 repertoire in the regulation of PLX-4032-induced pro-apoptotic signaling, we examined the effect of ABT-737, a small-molecule inhibitor to several antiapoptotic BCL-2 proteins (that is, BCL-2, BCL-xL and BCL-w; but not MCL-1). 21 ABT-737 is suggested to lower the threshold leading to apoptosis by preventing anti-apoptotic BCL-2 proteins from binding BH3-only proteins and/or by releasing BH3-only proteins from anti-apoptotic BCL-2 members to enhance BAK/BAX activation. 21 Returning to our hypotheses, we next determined whether ABT-737 pre-treatment revealed a pro-apoptotic signal in the majority of B-RAF V600E -inhibited cells.
In mouse models and the clinic, ABT-737 as a single therapy is well tolerated and does not cause any marked apoptosis phenotype. 21, 24 Indeed, the same is the case with A375 and SK-MEL-28 as ABT-737 treatment for up to 48 h resulted in no apoptosis, which is likely explained by MCL-1 expression (Figures 2a and b, Supplementary Figure S1C ; NB, ABT-737 does not inhibit MCL-1). 11 To directly examine our proposed above hypotheses, we co-treated cells with PLX-4032 and ABT-737 and measured apoptosis after 48 h. Pre-treatment with ABT-737 revealed dose-dependent apoptosis that was both rapid and robust (Figure 2c In order to better understand the relationship between cellular responses to B-RAF V600E inhibition and the anti-apoptotic BCL-2 proteins, we next implicated the mitochondrial pathway of apoptosis as a target downstream of PLX-4032 treatment. First, the pro-apoptotic protein BAX is often engaged following cellular stress leading to apoptosis, therefore we examined whether BAX became activated by the use of an active conformation-specific antibody (clone 6A7) following PLX-4032 and ABT-737 co-treatment. 25 A375 cells were treated with PLX-4032 and ABT-737 for 24 h, and the whole-cell lysates were subjected to 6A7 immunoprecipitation and western blotting. Indeed, the combination led to a marked increase in 6A7recognized BAX, whereas neither treatment alone resulted in significant recognition ( Figure 2g ). Second, as PLX-4032 and ABT-737 co-treatment results in BAX activation, we examined whether the anti-apoptotic protein BCL-xL could block the death response. Indeed, transient transfection of wild-type BCL-xL, but not a BAX-binding mutant (that is, BCL-xL G138A), prevented the majority of cell death induced by PLX-4032 and ABT-737 co-treatment ( Figure 2i ). Third, BCL-xL inhibited BAX activation, suggesting that our co-treatment results in cytochrome c release from mitochondria to the cytosol to initiate apoptosis. To directly examine this, we treated cells with PLX-4032 ± ABT-737 for 24 h, fractionated the cells into pellet ('p', contains mitochondria) and supernatant ('s', cytosolic proteins) and subjected these fractions to western blotting analysis for cytochrome c (Figure 2h ). As shown in figure 2h , the combination of PLX-4032 and ABT-737 resulted in marked cytochrome c redistribution from the pellet to the supernatant, whereas neither drug alone influenced cytochrome c localization. Finally, the combination of drugs led to a marked decrease in clonogenic survival in A375 and SK-MEL-28 (Figure 2j , Supplementary Figure S1D ). To broaden the relevance of these studies, we tested additional melanoma models: MALME-3E, MDA-MB-435 and WM266-4; and ABT-737 revealed dose-dependent apoptosis in all B-RAF V600E -positive lines ( Supplementary Figures S1E and G) .
The above data suggest that the anti-apoptotic BCL-2 family members are responsible for silencing the pro-apoptotic signal induced by the inhibition of oncogenic B-RAF V600E . We hypothesized that the anti-apoptotic proteins were directly inhibiting a PLX-4032-induced pro-apoptotic BCL-2 family member and therefore screened through all the pro-apoptotic BCL-2 proteins by preparing whole-cell lysates and western blotting studies. The majority of BCL-2 family proteins remained unchanged, except for BIM, which demonstrated a marked dose-dependent accumulation of two isoforms, BIM-EL and BIM-L following PLX-4032 treatment (Figure 3a ). BH3-only proteins bind with high affinity to anti-apoptotic BCL-2 proteins localized to the OMM, so we prepared heavy membrane fractions (commonly referred to as mitochondria) from PLX-4032-treated cells and were able to observe a marked PLX-4032-dependent accumulation of all three BIM isoforms, including the potent pro-apoptotic form, BIM-S (Figure 3b, Supplementary Figure S1H ). No other mitochondrialassociated BCL-2 family members demonstrated altered expression. We noted that the level of each BIM isoform was relatively modest in relationship to the anti-apoptotic BCL-2 proteins and that all BIM isoforms were exclusively localized to the heavy membrane fractions (that is, no unbound cytosolic BIM protein was detected), suggesting that the availability of anti-apoptotic BCL-2 proteins superseded the levels of expressed BIM (Figure 3c , Supplementary Figure S1H ), and this may be the mechanism explaining minimal pro-apoptotic responses following PLX-4032 treatment (Figures 1d and 2c , Supplementary Figure  S1C ). As control, ABT-737 did not regulate the expression of BIM in any cell line (Figure 3b , Supplementary Figure S1H ), and MeWo did not demonstrate PLX-4032-regulated BIM expression ( Figure 3d ). To ensure BIM was critical to PLX-4032-induced apoptosis, we stably silenced bim expression in A375 and SK-MEL-28 ( Figure 3e ) and examined cell death following PLX-4032 and ABT-737 co-treatment ( Figure 3f ). Indeed, silencing bim eliminated the majority of cell death induced by the PLX-4032 and ABT-737 combination treatment. We next hypothesized that ABT-737 could de-repress BIM from the inhibitory interaction with anti-apoptotic BCL-2 proteins at the OMM to promote cytochrome c release ( Figure 2h ) and apoptosis (Figure 2c , Supplementary Figure S1C ). To biochemically examine this hypothesis, we prepared heavy membrane fractions from PLX-4032-treated cells and tested for ABT-737-induced cytochrome c release in vitro. As shown in Figure 4a , heavy membranes from PLX-4032-treated A375 cells demonstrated dose-dependent cytochrome c release in response to ABT-737 addition; in contrast, mitochondria from A375 cells treated with DMSO elicited no response to ABT-737 ( Figure 4a ). C8-BID treatment is a positive control for BH3-only protein-induced cytochrome c release to ensure all mitochondrial isolations respond in vitro ( Figure 4a ), and mitochondria isolated from PLX-4032-treated MeWo are a negative control and demonstrated no response to ABT-737 ( Figure 4b ). The above observations demonstrate that: (1) the PLX-4032-mediated inhibition of oncogenic B-RAF V600E induces a pro-apoptotic signal that accumulates on mitochondria; (2) the pro-apoptotic signal remains silenced within B-RAF V600E cells via an interaction with PLX-4032 treatment phenotypes are regulated by BCL-2/BCL-xL anti-apoptotic proteins on the OMM; and (3) ABT-737 can reveal the PLX-4032-induced pro-apoptotic signal to engage cytochrome c release and cell death.
The data in Figures 3 and 4a suggest that BIM is involved in PLX-4032/ABT-737-induced cytochrome c release, therefore we directly tested this hypothesis by examining the cytochrome c releasing activity of BIM on purified mitochondria from A375 and MeWo. Mitochondria were isolated, treated with BIM, fractionated into pellet and supernatant and the fractions were analyzed by western blotting for cytochrome c. Indeed, treatment with the direct activator BIM was sufficient to promote rapid and complete cytochrome c release, while treatment with a sensitizer/derepressor BH3-only protein (for example, PUMA) or ABT-737 resulted in no cytochrome c release ( Figure 4c ). We interpret these results to suggest that, independent of B-RAF status, our model systems sustain the ability to induce cytochrome c release and apoptosis and that pro-apoptotic signaling upstream of BIM and mitochondria dictates cellular fate.
Our previous results suggested that BCL-xL could block PLX-4032-induced pro-apoptotic signaling (Figure 2i ), therefore we examined whether BIM-mediated cytochrome c release in vitro was also blocked by BCL-xL. The addition of BCL-xL completely inhibited BIM-induced cytochrome c release from both A375 and MeWo mitochondria, and furthermore, this inhibition was reversed by the addition of ABT-737 ( Figure 4d ), which parallels our cellular results (Figure 2c , Supplementary Figure S1C ). As control for our protein and mitochondrial purifications, we also provide evidence that MCL-1-mediated inhibition of BIM-induced cytochrome c release is only reversed by the addition of PUMA (NB, ABT-737 does not bind MCL-1), whereas PUMA or ABT-737 could de-repress the inhibitory activity of BCL-xL, (that is, PUMA and ABT-737 bind BCL-xL) ( Figure 4d ). 11, 13, 17, 21 In our experiments, we show that ABT-737 can promote PLX-4032-mediated apoptosis, presumably by releasing proapoptotic BIM from anti-apoptotic BCL-2 proteins localized to the OMM. We formally examined this hypothesis by determining whether BIM could be displaced from the OMM by the addition of ABT-737 in vitro. Mitochondria from PLX-4032-treated A375 cells were isolated, incubated with ABT-737 for 1 h before centrifugation and subjected to western blotting for BIM. PLX-4032 treatment promoted the accumulation of multiple BIM isoforms on the OMM (Figure 4e , left panel), and the addition of ABT-737 to these mitochondria resulted in a decreased presence of BIM isoforms (Figure 4e , right panel). For control, we also examined the effect of PUMA on the binding of BIM to these mitochondria. PUMA binds with high affinity to all anti-apoptotic BCL-2 proteins, and this should eliminate the majority of BIM associated with the OMM. Indeed, PUMA addition reduced BIM levels to mitochondria isolated from untreated A375 cells (Figure 4e ). To ensure that the release of BIM from the OMM was mediated by anti-apoptotic BCL-2 proteins, we immunoprecipitated BCL-xL from PLX-4032treated mitochondria ± ABT-737. As shown in Figure 4f , BCL-xL-BIM complexes were observed in PLX-4032-treated cells, but the addition of ABT-737 markedly reduced the level of BIM associated with BCL-xL. All together, these data suggest that ABT-737 can efficiently displace BIM from anti-apoptotic BCL-2 proteins on the OMM to promote apoptosis (Figures 4e and f) . Figures 3a and b show that multiple anti-apoptotic (that is, BCL-2/BCL-xL and MCL-1) and pro-apoptotic (that is, BAK/BAX, BIM and PUMA) BCL-2 family members likely regulate cellular sensitivity to cytochrome c release following PLX-4032 treatment. Furthermore, the requirement for ABT-737 within this complex BCL-2 family network reveals a unique dependence on BCL-2/BCL-xL to maintain survival following the inhibition of B-RAF V600E . To examine the exquisite dependency on ABT-737 to promote cytochrome c release, we modeled the BCL-2 family network observed in A375 cells using biochemically defined large unilamellar vesicles (LUVs) and recombinant BCL-2 family members. 14, 26 The LUVs are composed of the major lipid species that comprise mitochondrial membranes, and treatment of mitochondrial LUVs with BAX or BIM alone did not cause LUV permeabilization, but when combined, resulted in BIM-mediated dose-dependent BAX activation and LUV permeabilization ( Figure 4g ). As suggested in Figures 3a and d and 4e and f, BIM is the pro-apoptotic protein directly responsible for cytochrome c release, and similar results were obtained using the LUV system, as PUMA did not cause permeabilization alone or in the presence of BAX (Figure 4h ). Finally, we examined the integration of BAX, BCL-xL, BIM, MCL-1 and PUMA in the LUV system, which revealed that this unique combination of BCL-2 family proteins did not promote LUV permeabilization unless ABT-737 was added, suggesting that ABT-737 could specifically trigger BIM-mediated BAX activation in this setting (Figure 4i ).
From these data, we propose: (1) the pro-apoptotic signal mediated by the inhibition of oncogenic B-RAF V600E is the mitochondrial accumulation of multiple BIM isoforms; (2) the majority of pro-apoptotic BIM is silenced by the anti-apoptotic BCL-2 family leading to sustained survival; (3) ABT-737 reveals the pro-apoptotic activity of BIM to induce cytochrome c release and marked apoptosis; and (4) orally bioavailable derivates of ABT-737 (that is, ABT-263) may be a useful combination strategy with PLX-4032 to boost cell death responses early in chemotherapeutic regimens. 20 Patients treated with targeted therapies like PLX-4032 often experience prolonged survival, yet succumb to the rapid development of drug-resistant populations leading to few clinical options. 10 To evaluate the utility of ABT-737 in treating PLX-4032resistant populations, we created several PLX-4032-resistant h. The cells were then subjected to fractionation for cytosol and heavy membranes (that is, mitochondria), and these fractions were subjected to western blotting for cytochrome c. Supernatants (s) and pellets (p) are shown. 'Total' is a detergent (0.25% TX100) solubilized sample. (i) A375 were transiently transfected with empty vector, pcDNA3.1-BCL-xL WT or pcDNA3.1-BCL-xL G138A . The next day, cells were pre-treated with ABT-737 (1 μM) for 1 h before treatment with PLX-4032 (5 μM) for 48 h and analyzed by AnnexinV and flow cytometry. (j) A375 were pretreated with ABT-737 (1 μM) for 1 h before treatment with PLX-4032 (5 μM) for 48 h, the media was replaced, and the cells were cultured for an additional 10 days. The resulting colonies were stained (left panel) and quantified (right panel). The PLX-4032+ABT-737 combination is shown in triplicate. All data are representative of at least triplicate experiments, and reported as ± s.d., as required.
B-RAF V600E cell models using parental A375 and SK-MEL-28 cells and refer to these lines as 'A375 R ' and 'SK-MEL-28 R ', respectively. To characterize the lines, we removed PLX-4032 for 24 h before re-treating and subsequent analyses. A375 R and SK-MEL-28 R cells were treated with PLX-4032 for 24 h, and we analyzed responses to ERK phosphorylation status and cell cycle distribution. PLX-4032 treatment did not markedly change ERK signaling in A375 R (Figure 5a ) or SK-MEL-28 R (Supplementary Figure S3A) , and there were minimal changes to cell cycle distribution compared with the parental lines (Figure 5b , Supplementary Figure S3B ), both of which suggest bone fide PLX-4032 resistance. We next compared the apoptotic responses in the parental and resistant lines following PLX-4032 exposure. As shown in Figure 5c and Supplementary Figure S3C , A375 R and SK-MEL-28 R demonstrated markedly less cell death compared with the parental lines. Furthermore, A375 R also displayed parallel resistance to common inducers of apoptosis, for example, staurosporine and cycloheximide, but not VP16. This suggested to us that the resistant lines selectively silenced pro-apoptotic signaling following certain stresses but did not have a mutation in the core apoptotic signaling cascade (for example, APAF-1 or caspases-9/-3) or marked changes within the BCL-2 family (Figure 5d, Supplementary Figures S2A and B) .
To investigate a mechanism of selective apoptosis insensitivity in A375 R and SK-MEL-28 R , we next compared BIM expression and accumulation on mitochondria in the parental and PLX-4032resistant lines following PLX-4032 exposure. PLX-4032 treatment induced marked BIM expression ( Figure 5e ) and mitochondrial accumulation (Figure 5f ) in the parental A375 line, but these responses were severely blunted in A375 R , which also paralleled Figure 3 . PLX-4032 induced inhibition of B-RAF V600E promotes marked expression and rapid mitochondrial accumulation of BIM; however, this pro-apoptotic signal remains silenced. (a) A375 was treated with PLX-4032 (5 μM) for the indicated time points before western blotting for the indicated BCL-2 family members. GAPDH is shown as a loading control. (b) A375 cells were pre-treated with ABT-737 (1 μM) for 1 h before treatment with PLX-4032 (5 μM) for 24 h. The heavy membrane fractions ('HM' , that is, mitochondria) were then analyzed for the indicated BCL-2 family members. HSP60 is shown as a loading control. (c) A375 cells were treated with PLX-4032 (5 μM) for 24 h and fractionated into cytosol and heavy membranes. These fractions were subjected to western blotting for BIM. SMAC is shown as a mitochondrial loading control. (d) A375 and MeWo were treated with PLX-4032 (5 μM) for 24 h; the HM fractions were isolated and subjected to western blotting analysis for BIM. SMAC is shown as a mitochondrial loading control. (e) A375 and SK-MEL-28 cells stably expressing bim shRNA (or the control vector, pLKO.1) were quantified for bim knock down by quantitative PCR. Expression was normalized with β-actin and gapdh. the lack of apoptosis (Figure 5c ). Likewise, A375 R failed to induce bim mRNA compared with the parental A375 line after PLX-4032 treatment (Figure 5g) . Despite not being able to detect significant BIM mRNA or protein accumulation in A375 R , ABT-737 pre-treatment was able to reveal a pro-apoptotic signal following PLX-4032 treatment, suggesting that either minimal BIM induction or an unimplicated BH3-only protein was functional to promote apoptosis (Figure 5h) . Importantly, the above observations were reproducible in SK-MEL-28 R (Supplementary Figures S3D  and E) .
In addition to B-RAF V600E -specific therapies, drugs inhibiting other components of the MAPK signaling pathway (that is, MEK) and conventional chemotherapeutic agents are often used to treat metastatic melanoma. 19, 27 For this reason, and the observed apoptotic resistance presented in Figures 5c and g and Supplementary Figures S3C and E , we were interested in investigating whether the A375 R and SK-MEL-28 R lines maintained sensitivity to another targeted therapy (that is, GSK-110212, a MEK inhibitor) and/or conventional chemotherapeutic agents used to treat metastatic disease (for example, cisplatin, dacarbazine and vinblastine). A375 R and SK-MEL-28 R lines displayed marked resistance to GSK-110212-induced apoptosis, compared with the parental lines ( Supplementary Figures S4A and B ). Furthermore, A375 R were also resistant to the cisplatin-, dacarbazine-and vinblastine-induced apoptosis (Figure 5i ), but this phenotype did not extend to the SK-MEL-28 R line ( Supplementary Figures S3F  and G) . To determine the role of the anti-apoptotic BCL-2 repertoire in mediating the marked resistance in A375 R , we pretreated the resistant line with ABT-737 and then exposed the cells to GSK-1101212, cisplatin, dacarbazine or vinblastine. Interestingly, re-sensitization of A375 R to cell death induced by all of these drugs was achieved with ABT-737 in a manner similar to parental A375 (Figure 5j, Supplementary Figures S4A, B and D) , indicating that the anti-apoptotic BCL-2 repertoire may be of significant clinical utility following acquired drug resistance.
To extend our findings that anti-apoptotic BCL-2 family inhibition may enhance treatment success when cancer cells display resistance to PLX-4032, as suggested by in vitro experiments using A375 R and SK-MEL-28 R (Figure 5h and Supplementary  Figures S3E) , we next examined SK-MEL-28 R melanoma xenografts. Instead of using ABT-737 for these experiments, we switched to ABT-263, a small-molecule inhibitor that displays nearly identical binding properties to anti-apoptotic BCL-2 proteins compared with ABT-737, but ABT-263 is orally bioavailable and administered to patients. 20 First, we compared ABT-263 and ABT-737 for the ability to enhance PLX-4032-induced apoptosis in SK-MEL-28 and SK-MEL-28 R . As shown in Figures 6a  and b , ABT-263 and ABT-737 functioned equivalently to sensitize both cell lines to PLX-4032-induced apoptosis. Next, we generated SK-MEL-28 R xenografts (Figure 6c ) and then treated these tumorbearing mice with a daily oral gavage of PLX-4032 (100 mg/ kg) ± ABT-263 (10 mg/kg) for 1 week, which is half the dose and average treatment duration for PLX-4032 regimens in melanoma patients. Control (vehicle injected) or ABT-263 treatment alone resulted in minimal changes in tumor growth; however, we noted PLX-4032 treatment resulted in larger tumors compared with control ( Figure 6d ). Despite the increase in tumor volume induced by PLX-4032 treatment, the combination of PLX-4032 and ABT-263 resulted in a marked decrease in tumor growth and subsequent increases in TUNEL (terminal deoxinucleotidyl transferasemediated dUTP-fluorescein nick end labeling) positivity, a marker of apoptosis (Figures 6d and f) . Importantly, there were no marked changes to tumor cell proliferation (Figures 6g and h,  Supplementary Figure S5A ) or tumor vascularization (Supplementary Figure S5B ) among the treatment groups. It should be noted that we observed that SK-MEL-28 R tumors grew with greater size heterogeneity compared with the parental SK-MEL-28 line (Figure 6c and Supplementary Figure S6A ). SK-MEL-28 R average tumor volumes before and after treatment, along with the range in tumor sizes, are provided in Supplementary Figure S6B . Finally, we ensured that the PLX-4032 in the in vivo treatments was effective against parental SK-MEL-28 tumors, so we evaluated SK-MEL-28 xenografts for PLX-4032 responses. Indeed, PLX-4032-treated SK-MEL-28 tumors responded as there was an observable decrease in tumor volume ( Supplementary Figure S6C) .
DISCUSSION
The conclusions from our work reveal the mechanism of action for synergy between the parallel inhibition of B-RAF V600E signaling and the anti-apoptotic BCL-2 family repertoire (Figures 2, 3, 4, 5, 6 ). Furthermore, our data suggest that collateral inhibition of the antiapoptotic BCL-2 repertoire with ABT-737 (or the orally bioavailable form, ABT-263) may provide a much-needed clinical opportunity to increase primary response rates to targeted therapies like PLX-4032 and GSK-110212. This combination may decrease the chances of chemoresistance as the concentrations of drugs required to achieve a durable response will likely be lower (Figure 6d ), and many more tumor cells will be eliminated ( Figures  2c, 5h, 6a and b, Supplementary Figures S1C, S1E, S3E, S4A and B,  S4D, S6C ). In addition, if PLX-4032 resistance is unavoidable, ABT-737/263 may assist in re-sensitizing patients to additional targeted therapies as suggested by our data and other publications ( Supplementary Figures S4A and B) 28 and may increase the response rates to conventional chemotherapeutic strategies (Figure 5j, Supplementary Figures S3F, G and S4D ). Although our data have been generated in several commonly used laboratory models of B-RAF V600E and melanoma biology, the utility of our biochemical and promising cellular results must be explored using in vivo genetic model systems to fully appreciate their likelihood of benefiting patients.
MATERIALS AND METHODS Reagents
All cell culture and transfection reagents were from Invitrogen (Carlsbad, CA, USA); and standard reagents were from Sigma-Aldrich (St Louis, MO, USA) or Fisher Scientific (Hampton, NH, USA). Drugs were from: ABT-737 (Abbott Laboratories, Abbott Park, IL, USA), ABT-263/PLX-4032/GSK-110212 (Selleck), zVAD-fmk (Calbiochem/Millipore, Darmstadt, Germany), Hoechst 33342 (Anaspec, Fremont, CA, USA), and staurosporine/cisplatin/dacarbazine/vinblastine (Sigma-Aldrich). Antibodies (clone) were: anti-actin (C4), anti-A1 (FL-175), anti-BCL-2 (100), anti-CD31 (BD Pharmingen, San Diego, CA, USA, No.550274) anti-MCL-1 (Rockland, Gilbertsville, PA, USA), anti-BAD (C7), anti-BIM (22-40), anti-PUMA (CT; Sigma-Aldrich), anti-SMAC (H177), anti-BID (C20), anti-cytochrome c (7H8.2C12), anti-BAK (G23), anti-BAX (6A7 for IP; N20 for western blotting), anti-BCL-xL (H5 for IP; S18 for western blotting), anti-GAPDH (anti-glyceraldehyde 3-phosphate dehydrogenase; 9B3), anti-HSP60 (B-9), anti-p44/p42 MAPK ERK1/2 (137F5), and antiphospho p44/42 MAPK ERK1/2 (197G2). Caspase-8 cleaved mouse BID (C8-BID) was from R&D Systems (Minneapolis, MN, USA). Full-length BAX was made as described. 29 Human BCL-xLΔC, MCL-1ΔC and PUMAβ were made as described. 17 The human BIM BH3 domain peptide (>98% purity, Abgent, San Diego, CA, USA) was resuspended in anhydrous DMSO in a N 2 environment, stored at − 80°C and thawed only once. All lipids for the LUVs studies were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Statistical significance was evaluated by two-tailed Student's t-test for Po0.05.
Cell culture, transfection, apoptosis and clonogenic survival assays A375, MALME-3M, MeWo, MDA-MB-435, SK-MEL-28 and WM266-4 lines were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 2 mM L-glutamine, and antibiotics. Cells were transfected (85 000 cells per well/12-well plate, cultured overnight before transfection) using Lipofectamine2000 (Invitrogen) according to the manufacturer's instructions for 6 h under serum-free conditions. Green fluorescent protein (pUS9-GFP, 100 ng) was co-transfected as an efficiency marker (30-50% of cells were usually transfected). For cell death studies, cells were seeded for 24 h, treated as described, floating and attached cells were harvested, stained with AnnexinV-FITC in binding buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 ) and analyzed by flow cytometry as indicated. 30 For clonogenic survival studies, cells were treated with the indicated drugs for 24 h before changing the media. Colonies were stained with methylene blue 10 days after treatment and imaged. Colonies were then de-stained (20% methanol in 5% acetic acid), and the supernatant was measured for absorption at 520 nm for quantification of the wells. To generate PLX-4032-resistant lines, A375 and SK-MEL-28 were cultured in 1 and 5 μM PLX-4032, respectively, until proliferation rates returned
